Evidence for the efficacy of immunotherapy in children with high-risk neuroblastoma
Elwira Szychot1, Jarosław Peregud-Pogorzelski2, Paweł Wawryków2
1The Institute of Cancer Research, London, UK.
Insights
High-risk neuroblastoma, a common childhood cancer, often relapses after intensive treatment. Combined immunotherapy with anti-GD2 antibodies shows promise but requires further study for long-term benefits.
Area of Science:
- Pediatric Oncology
- Immunology
- Cancer Therapeutics
Background:
- Neuroblastoma is the most frequent pediatric extra-cranial malignancy, primarily affecting children under four.
- Prognosis is influenced by diagnosis age, disease stage, and molecular genetics, with over 50% of cases classified as high-risk.
- Standard high-risk neuroblastoma therapy includes intensive chemotherapy, surgery, radiotherapy, stem cell rescue, and retinoic acid, yet over half of patients relapse.
Purpose of the Study:
- To evaluate the efficacy of combined immunotherapy for high-risk neuroblastoma.
- To explore the immunological mechanisms underlying anti-GD2 antibody therapy.
- To determine the long-term benefits of current treatment strategies.
Main Methods:
- Review of randomized trials on combined therapy including anti-GD2 monoclonal antibodies, interleukin-2 (IL-2), granulocyte-macrophage colony-stimulating factor (GM-CSF), and 13-cis-retinoic acid.
- Analysis of immunological processes involved in anti-GD2 antibody treatment.
- Assessment of patient relapse rates and long-term outcomes.
Main Results:
- Combined immunotherapy has demonstrated effectiveness in some randomized trials.
- Understanding immunological responses to anti-GD2 antibodies is crucial for accurate evaluation.
- Relapse rates remain high despite intensive treatment protocols.
Conclusions:
- Combined immunotherapy, including anti-GD2 antibodies, offers a potential treatment avenue for high-risk neuroblastoma.
- Further research into immunological mechanisms is needed to optimize anti-GD2 antibody therapy.
- The long-term efficacy and benefit of this combined approach require further investigation and establishment.
Abstract:
Neuroblastoma is the most common extra-cranial malignancy of childhood, with the highest incidence in children younger than 4 years. The prognosis depends on many factors, such as age at diagnosis, stage of disease and molecular genetic subtype. More than 50% of children who present with the disease are deemed to have high-risk neuroblastoma. The standard therapy for children with high-risk neuroblastoma consists of intensive chemotherapy, surgery, radiotherapy, myeloablative consolidation with autologous haematopoietic stem cell rescue followed by the treatment of minimal residual disease with 13-cis-retinoic acid. Unfortunately, more than half of the patients relapse regardless of the treatment intensity. Combined therapy with monoclonal antibodies (anti-GD2), intravenous interleukin-2 (Il-2), intravenous granulocyte-macrophage colony-stimulating factor (GM-CSF) and oral 13-cis-retinoic acid have been proved to be effective in some randomised trials. A better understanding of the underlying immunological processes in therapy with anti-GD2 antibodies will allow its success to be evaluated more accurately and direct future endeavours. Nevertheless, the long-term benefit of this treatment approach needs to be established.
